Clinical Trial Update: A Phase I/II, Open Label, Escalating Dose, Pilot Study to Assess Effect, Safety, Tolerability and PK of Multiple SC Doses of Drisapersen in Patients With Duchenne Muscular Dystrophy and to Assess the Potential for IV Dosing as an Alternative Route of Administration [Phase 2]

View source ↗

Summary

Phase I/II open-label escalating-dose pilot study of subcutaneous Drisapersen in Duchenne muscular dystrophy to assess safety, tolerability, pharmacokinetics, a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• Drisapersen (drisapersen)

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Muscular Dystrophies | Phase 2 | Status: TERMINATED